Canada markets open in 5 hours 25 minutes

HUTCHMED (China) Limited (HCM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.48+0.07 (+0.49%)
At close: 04:00PM EST
14.48 0.00 (0.00%)
After hours: 04:30PM EST

HUTCHMED (China) Limited

Cheung Kong Center
48th Floor 2 Queen's Road
Central
Hong Kong
852 2121 8200
https://www.hutch-med.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees1,990

Key Executives

NameTitlePayExercisedYear Born
Mr. Chi Keung To ACGI, B.Sc., M.B.A.Executive Chairman85kN/A1952
Dr. Wei-Guo Su B.Sc., Ph.D.CEO, Chief Scientific Officer & Executive Director1.97MN/A1959
Mr. Chig Fung Cheng BEc, CACFO & Executive Director886kN/A1967
Ms. Edith Shih BSE, C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., P.ECompany Secretary & Non-Executive DirectorN/AN/A1952
Dr. Karen Jane AtkinExecutive VP & COON/AN/A1966
David NgHead of Investor Relations & Capital StrategiesN/AN/AN/A
Mr. Charles George Rupert NixonGroup General CounselN/AN/A1970
Mr. Kin Hung Lee M.B.A.Senior Vice President of Corporate Management & CommunicationsN/AN/A1977
Ms. Selina ZhangSenior Vice President of Global Human ResourcesN/AN/AN/A
Dr. Qingmei Wang Ph.D.Senior Vice President of Business Development & Strategic AlliancesN/AN/A1963
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Corporate Governance

HUTCHMED (China) Limited’s ISS Governance QualityScore as of February 1, 2024 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.